Zydus margin rebounds sharply, but profit remains below last year's base
Sequential revenue growth and lower expenses lifted operating margin to 53.17%, while other income contributed 18.39% of pre-tax profit.
Filed 19 May 2026, 14:09 IST · Zydus Lifesciences Ltd (ZYDUSLIFE)
Key takeaways
- Standalone operating margin rebounded 44.46 percentage points sequentially to 53.17% as revenue rose +63.82% while expenses fell -15.96%.
- Year-on-year net profit fell -38.80% because revenue declined -35.72% and operating margin narrowed 11.66 percentage points, despite a 5.00-percentage-point tax-rate reduction.
- The stock gained +8.87% five sessions after the results, above its 3.60% median absolute reaction across the last eight results.
Price around the results
Operating recovery from the Q3 trough
Zydus Lifesciences reported standalone revenue of Rs 3,740.9 cr and net profit of Rs 1,722.0 cr in Q4FY26. The sequential improvement was driven by revenue growth of +63.82% alongside a -15.96% decline in expenses, lifting operating margin by 44.46 percentage points. Year on year, however, revenue was down -35.72% and net profit fell -38.80%.
Margin recovery was partly offset by profit-quality factors
Year-on-year costs fell only -14.42% against the -35.72% revenue decline, so operating margin narrowed 11.66 percentage points. Other income of Rs 388.3 cr accounted for 18.39% of pre-tax profit, making it a material contributor to reported earnings. The tax rate was 18.43%, down 5.00 percentage points year on year, which also cushioned the decline in net profit.
Margin remains well above the healthcare peer median
The 53.17% operating margin was 29.79 percentage points above the 23.38% median for the 48 healthcare peers that had reported the quarter. The quarterly pattern has been uneven: margin moved from 64.83% in Q4FY25 to 22.62% in Q1FY26, 40.12% in Q2FY26, 8.71% in Q3FY26 and then 53.17% in Q4FY26. This is a rebound from the previous quarter, not a third consecutive decline.
Launches and capacity investment shape the next read-through
Management said North America base-business volume expansion and new launches drove growth, while North America Formulations sales still declined 5.7% year on year in Q4FY26. The company told investors it launched six products in North America, filed three ANDAs and received approval for nine ANDAs; it also launched Tishtha, described as the world's first biosimilar of Nivolumab, and Zycubo for Menkes disease. Management reported organic capex of Rs 3,577 mn for the quarter and said it targets 50% of energy requirements from renewables by 2030, net water neutrality by 2028 and net carbon neutrality by 2035.
Market reaction was stronger than its usual results move
The stock rose +2.80% on the results date, +5.02% after one session and +8.87% after five sessions. That five-session move was above the 3.60% median absolute move across the last eight result reactions, six of which were positive and two negative. The results-date trading volume was 5.48 times the reference level.
Q4FY26 at a glance
Standalone figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹3,741 cr | ₹2,284 cr | +63.82% | -35.72% |
| Other income | ₹388 cr | ₹414 cr | -6.14% | +109.44% |
| Expenses | ₹1,752 cr | ₹2,085 cr | -15.96% | -14.42% |
| Operating profit | ₹1,989 cr | ₹199 cr | +899.55% | -47.28% |
| Operating margin (%) | 53.17% | 8.71% | — | — |
| Interest | ₹116 cr | ₹116 cr | -0.43% | -25.68% |
| Depreciation | ₹151 cr | ₹144 cr | +4.57% | +17.89% |
| Profit before tax | ₹2,111 cr | ₹352 cr | +499.04% | -42.55% |
| Tax | ₹389 cr | ₹56 cr | +595.89% | -54.82% |
| Net profit | ₹1,722 cr | ₹297 cr | +480.78% | -38.80% |
| EPS (₹) | ₹17.11 | ₹2.95 | +480.00% | -38.81% |
Operating margin of 53.17% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +2.80% | +2.94% |
| Next session | +5.02% | — |
| 5 sessions | +8.87% | +7.76% |
| 15 sessions | +10.82% | — |
| 30 sessions | +10.97% | — |
Volume on the results session was 5.48× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- North America base business volume expansion and new launches drove growth.
Guidance & outlook
- The company targets net water neutrality by 2028.
- The company targets net carbon neutrality by 2035.
- The company targets sourcing 50% of its energy requirements from renewable sources by 2030.
- The company plans to increase waste disposal through co-processing by 40% for India operations by 2026.
Expansion
- Organic capex was Rs. 3,577 million in the quarter.
New products
- The company launched six new products in North America.
- The company launched Zycubo for ultra-rare Menkes disease.
New initiatives
- The company launched Tishtha, the world's first biosimilar of Nivolumab.
- The company filed three ANDAs and received approval for nine ANDAs.
- The company adopted a focused, therapy-led approach in emerging markets to build a more agile portfolio.
Competition
- The company retained its leadership position in oncology therapy.
Problems & risks
- North America Formulations sales declined 5.7% year over year in Q4 FY26.
What to watch
- Whether standalone operating margin holds above 53.17% after the Q4FY26 rebound.
- Whether North America Formulations sales recover from the reported 5.7% year-on-year decline.
- Whether other income remains below or above its 18.39% share of pre-tax profit.